<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684004</url>
  </required_header>
  <id_info>
    <org_study_id>02.12.20</org_study_id>
    <nct_id>NCT04684004</nct_id>
  </id_info>
  <brief_title>Hyperglycemia in Patients With Takotsubo Syndrome</brief_title>
  <official_title>Blood Glucose Values at Hospital Admission and Clinical Outcomes in Patients With Takotsubo Syndrome: Hyperglycemia Effects on Heart Failure Events and Mortality at 24 Months of Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Takotsubo cardiomiopathy (TTC) have over-inflammation and over-sympathetic&#xD;
      tone. However, these conditions could cause higher rate of heart failure (HF) events and&#xD;
      deaths at 2 years of follow-up. Conversely, hyperglycemia vs. normoglycemia could result in&#xD;
      over expression of inflammatory markers and catecholamines thta could result in higher rate&#xD;
      of HF and deaths at 2 years of follow-up in TTC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of HF events</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the number of HF events by clinical visits, telephonic interviews and hospital discharge schedules.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Takotsubo Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>TTC patients with hyperglycemia</arm_group_label>
    <description>These patients will be hospitalized for TTC acute event. These patients will be characterized by higher blood glucose values at admission, and so defined as hyperglycemics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTC patients with normoglycemia</arm_group_label>
    <description>These patients will be hospitalized for TTC acute event. These patients will be characterized by normal blood glucose values at admission, and so defined as normoglycemics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>To report number of HF events and deaths</intervention_name>
    <description>In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.</description>
    <arm_group_label>TTC patients with hyperglycemia</arm_group_label>
    <arm_group_label>TTC patients with normoglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be of patients with acute TTC event. The enrolled patients&#xD;
        according to inclusion and exclusion criteria will be then divided in normoglycemics vs.&#xD;
        hyperglycemics according to blood glucose values at hospital admission.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute onset of a cardiovascular event, usually associated with substernal chest pain,&#xD;
             initially regarded as STEMI/evolving coronary syndrome;&#xD;
&#xD;
          -  cardiac biomarker modifications (creatine kinase-MB and troponin I);&#xD;
&#xD;
          -  systolic dysfunction, predominantly characterized by akinesia/hypokinesia of the&#xD;
             mid-to-distal portion of the left ventricle (LV) chamber, with hyper-contractile basal&#xD;
             LV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with previous previous myocardial infarction;&#xD;
&#xD;
          -  patients with previous TTC event;&#xD;
&#xD;
          -  patients affected by chronic kidney, liver, and cerebrovascular diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Raffaele Marfella</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Celestino Sardu</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

